Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?

Aug 10 2018

• By Mandy Jackson

Hitting bigger business target

Related Content

Teva Braces For A Bigger Hit As Price Competition Intensifies For Copaxone

Aug 02 2018

Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value

Aug 08 2018

Perrigo Generic Of Teva's ProAir Stunned By Another FDA CRL

May 14 2018

Perrigo's OTC Core Could Expand To Include National Brands

Aug 10 2018

Perrigo Taps CEO With Global Operations Expertise At Pharma Packaging Firm

Jan 09 2018

Perrigo Finding Balance As Three-Legged Stool With Two Consumer Units, Rx Division

Mar 05 2018

Starboard Agreement Tilts Perrigo Toward Rx Generics Sale

Feb 07 2017

Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him

Jun 06 2017

Perrigo Puts Tysabri On Block, Generic Topicals Under Microscope

Nov 11 2016

Perrigo's Rx Business Looks Ready To Sell, Says Hedge Fund Investor

Sep 13 2016

Generic Manufacturers Try To Up Their Game As US Pressure Persists

Jun 16 2017

Starboard-Driven Perrigo Sees CEO Depart After CFO

Jun 06 2017

Related Companies

Perrigo Company PLC

Viatris Inc.

Teva Pharmaceutical Industries Ltd.

Additional Topics

Business Strategies Generic Drugs Companies Sales & Earnings Commercial BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window